Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) EBITDA Margin (2018 - 2025)

Arcturus Therapeutics Holdings' EBITDA Margin history spans 8 years, with the latest figure at 404.1% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 27230.0% year-over-year to 404.1%; the TTM value through Dec 2025 reached 80.19%, down 2705.0%, while the annual FY2025 figure was 80.19%, 2705.0% down from the prior year.
  • EBITDA Margin reached 404.1% in Q4 2025 per ARCT's latest filing, down from 78.41% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 73.21% in Q4 2022 to a low of 2727.69% in Q2 2021.
  • Average EBITDA Margin over 5 years is 541.79%, with a median of 79.0% recorded in 2025.
  • Peak YoY movement for EBITDA Margin: tumbled -228570bps in 2021, then soared 264810bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 667.29% in 2021, then soared by 111bps to 73.21% in 2022, then plummeted by -152bps to 37.94% in 2023, then tumbled by -247bps to 131.8% in 2024, then crashed by -207bps to 404.1% in 2025.
  • Per Business Quant, the three most recent readings for ARCT's EBITDA Margin are 404.1% (Q4 2025), 78.41% (Q3 2025), and 32.44% (Q2 2025).